AP-101
Non-Small Cell Lung Cancer (NSCLC) with specific mutations
Key Facts
About Advance Pharmaceutical
Advance Pharmaceutical is dedicated to translating scientific discoveries into transformative medicines for patients with high unmet medical needs. The company's core technology enables the precise targeting of disease pathways, particularly in oncology and genetic disorders. With a robust pipeline of candidates in various stages of development and a strong leadership team, the company is strategically positioned for growth. Its focus on both internal development and strategic partnerships aims to accelerate the delivery of new therapies to market.
View full company profileAbout Neurimmune
Neurimmune is a Swiss, privately-held biotech founded in 2006, specializing in discovering and developing first-in-class antibody therapeutics for protein aggregation diseases. Its core Reverse Translational Medicine™ platform analyzes immune cells from elderly donors to generate fully human antibodies with high selectivity and low immunogenicity risk. The company has built a diversified clinical-stage pipeline targeting ATTR-CM, ALS, and Alzheimer's, advancing programs through strategic partnerships with major pharma while retaining early-stage innovation autonomy.
View full company profile